HTLZF (Hamilton Thorne) 5-Year EBITDA Growth Rate : -0.80% (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Hamilton Thorne 5-Year EBITDA Growth Rate?

Hamilton Thorne's EBITDA per Share for the three months ended in Sep. 2024 was $0.01.

During the past 12 months, Hamilton Thorne's average EBITDA Per Share Growth Rate was 46.50% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 2.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -0.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Hamilton Thorne was 42.60% per year. The lowest was 2.50% per year. And the median was 25.30% per year.

Competitive Comparison of Hamilton Thorne's 5-Year EBITDA Growth Rate

For the Medical Devices subindustry, Hamilton Thorne's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hamilton Thorne's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Hamilton Thorne's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Hamilton Thorne's 5-Year EBITDA Growth Rate falls into.

Hamilton Thorne 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Hamilton Thorne (OTCPK:HTLZF) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Hamilton Thorne 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Hamilton Thorne's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Hamilton Thorne Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hamilton Thorne Ltd (OTCPK:HTLZF) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

0ZM:Germany HTL:Canada

Address

100 Cummings Center, Suite 465E, Beverly, MA, USA, 01915

Website

https://www.hamiltonthorne.ltd

Hamilton Thorne Ltd is engaged in providing precision instruments, consumables, software, and services that reduce cost, increase productivity, improve results, and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets. The company markets its products and services under the Hamilton Thorne, Gynemed, and Embryotech Laboratories brands, through its growing sales force and distributors. The company's customer base consists of fertility clinics, university research centers, animal breeding facilities, pharmaceutical companies, biotechnology companies, and other commercial and academic research establishments. It has a single reporting segment being Engaged in Sales to the ART, Research, and Cell Biology Markets.